

CURZA, APTUIT JOIN FORCES TO TEST NOVEL ANTIBIOTICS

Titled “Synthetic and biological investigations of 2-aminoimidazole derived natural products”

SALT LAKE CITY, Utah—March 1, 2017— Curza, a privately-held small-molecule drug development company, has entered into a partnership with Aptuit, a pharmaceutical services company out of Verona, Italy, to expedite the process of advancing their ribosomal antibiotic program.

This partnership will take advantage of the partner research organization’s deep expertise in integrated infectious disease drug discovery, including in vitro and in vivo capabilities. Their capabilities will help Curza as they look to conduct IND-enabling studies.

About Curza— Curza is a Utah-based drug development company focused on developing novel therapeutics to combat antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and is backed by Clarke Capital Partners and other private investors. Visit www.curza.com for more information.

About Aptuit—Aptuit is a pharmaceutical services company that delivers early discovery to mid-phase drug development solutions and employs leading scientists in their field. With Drug Design & Discovery, API Development and Manufacture, Solid State Chemistry, CMC, Preclinical and IND enabling GLP/GMP programs, they offer the most complete set of early stage drug discovery capabilities in their field. Their UK, Italy, and Switzerland facilities offer fully integrated drug discovery & development services.

For media inquiries, please contact: Ryan Davies at rd@curza.com